The purposes of this network were to provide the mutational analysis of TP53 and IGHV genes to the Spanish centers diagnosing patients with CLL, and to educate hematologists on the need for performing a molecular assessment of CLL patients to guide the therapeutic strategies. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.